Luminex Plc · CSELK:LUMX.N0000
Luminex — Investor Presentation (May 2020)
20 slides from Luminex's investor presentation, May 14, 2020
Slide 1: Investor Presentation May 2020
INVESTOR PRESENTATION MAY 2020 Homi Shamir, President and CEO
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation is being made exclusively to investors that are both institutional accredited investors (within the meaning of Rule 501 promulgated under the Securities Act of 1933, as amended (the “Securities Act”)) (“IAIs”) and qualified institutional buyers (“QIBs”) as def
Slide 3: Overview
OVERVIEW MOLECULAR LIFE SCIENCE & DIAGNOSTICS CLINICAL TOOLS (MDx) (Tools) LICENSED FLOW TECHNOLOGIES AUTOMATED NON-AUTOMATED CYTOMETRY GROUP (LTG) complexity simplified. Recurring revenue items 3
Slide 4: Overview (Cont'd) 2019
OVERVIEW (Cont’d) 2019 Note: all figures approximate $335M M Dx TOOLS $137M $194M LICENSED FLOW TECHNOLOGIES AUTOMATED NON-AUTOMATED CYTOMETRY GROUP (LTG) $76M $61M $149M $45M complexity simplified. Recurring revenue items 4
Slide 5: Overview (Cont'd) Q1 2020
OVERVIEW (Cont’d) Q1 2020 Note: all figures approximate $90.4M +$8.0M/+10% M Dx vs. Q1 2019 TOOLS $45.2M $43.3M +$9.9M/+28% -$2.9M/-6% vs. Q1 2019 vs. Q1 2019 LICENSED FLOW TECHNOLOGIES AUTOMATED NON-AUTOMATED CYTOMETRY GROUP (LTG) $26.3M $18.9M $36.8M $6.5M +$7.3M/+38% +$2.6M/+16% +$1.9M/+5% -$4.9M
Slide 6: Our Recent 5-Year Journey
OUR RECENT 5-YEAR JOURNEY SIGNIFICANT REVENUE INCREASE: $227M TO $335M FROM 2014 TO 2019, 8% REVENUE CAGR 12% REVENUE CAGR (Ex-LabCorp) VERIGENE® II GI FDA ARIES® Submission 7 FDA Clearances Flow Cytometry Acquisition Nanosphere Acquisition Homi Shamir Joins Luminex NOV as CEO 2019 2015- 2019 JAN JU
Slide 7: Innovation, Execution, New Products
Innovative INNOVATION, EXECUTION, Pipeline NEW PRODUCTS Numerous Additional COVID-19 Solutions Guava Next Gen System 2021 ® & xMAP BEYOND INTELLIFLEX VERIGENE® II Initial 2020 COVID-19 Dx Solutions 2020 2020 2020 2020 complexity simplified. 7
Slide 8: Recent Highlights / New Products
RECENT HIGHLIGHTS/ NEW PRODUCTS 8
Slide 9: COVID-19 Solutions
COVID-19 SOLUTIONS PCR-BASED TESTS look for the virus’s genetic material in saliva or mucus Currently, there are three types of samples to diagnose people who commercially available tests: are currently infected with the PCR-based, antigen and antibody. novel coronavirus. Luminex’s multiplexed PCR-b
Slide 10: Multiple COVID-19 Solutions for the Long-Run
MULTIPLE COVID-19 SOLUTIONS FOR THE LONG-RUN ARIES® • Targeted, sample-to-answer diagnostic testing Molecular VERIGENE® • Syndromic, sample-to-answer diagnostics and surveillance Testing • Syndromic, high-throughput, cost-effective diagnostic testing ® MAGPIX • SARS-CoV-2 serology testing for immuni
Slide 11: Luminex's Portfolio Suited for All Phases of COVID-19
LUMINEX’S PORTFOLIO IS IDEALLY SUITED FOR ALL PHASES OF COVID -19 xMAP® Guava® ARIES® VERIGENE® VERIGENE® II MAGPIX® LX200/FM3D INTELLIFLEX easyCyte™ ImageStream® Description Molecular Dx MDx / Serology Serology Life Science Research Instruments Summer 2020 Test Kits In Dev. In Dev.
Slide 12: New and Transformative Era for Luminex
NEW AND TRANSFORMATIVE ERA FOR LUMINEX ANTICIPATED PLANNED LAUNCH OF 3 NEW PLATFORMS IN 2020 1 VERIGENE® II* ‒ Designed to offer flexibility like never before ‒ Launch expected in mid-2020, if cleared 2 xMAP® INTELLIFLEX ‒ Designed to provide modern enhancements for the gold standard multiplexing pl
Slide 13: Scaling Up Molecular Test Capacity to Address COVID-19
SCALING UP MOLECULAR TEST CAPACITY TO ADDRESS COVID-19 SHIPMENTS CAPACITY Q4 2019 EOQ1 Run Rate EOQ2 Run Rate By EOY 2020 ® RPP Panel: COVIDP -19 EUA: COVID-19 EUA: COVID-19 EUA: NxTAG 93,500 Tests/mo. 380,000 Tests/mo. 760,000 Tests/mo. 760,000 Tests/mo. ® Flu Panel: COVID-19 ASR: COVID-19 EUA: COV
Slide 14: Financial Overview
FINANCIAL OVERVIEW 14
Slide 15: Q1 2020A Revenue
Q1 2020A REVENUE $ in thousands PY Variance: Q1 2020 Q1 2019 $ % TOTAL MDx 45,237 35,291 9,946 28% System Revenue 6,266 6,046 220 4% Consumable Revenue 12,360 10,258 2,102 20% Royalty Revenue 13,078 13,972 (894) -6% Other Partner | Life Science 5,048 4,625 423 9% PARTNERS | LIFE SCIENCE 36,752 34,90
Slide 16: Q1 2020A Operating Results
Q1 2020A OPERATING RESULTS $ in thousands Q1 2020 Q1 2019 Variance from PY PY Variance % Revenue $ 90,424 $ 82,408 $ 8,016 10% Cost of Revenue 40,078 36,601 (3,477) -9% Gross Margin 50,346 45,807 4,539 10% Gross Margin % 55.7% 55.6% 0.1% Operating Expenses: R&D 11,918 15,048 3,130 21% R&D % 13% 18%
Slide 17: Guidance
GUIDANCE • Expecting Q2 2020 revenue to equal or exceed $105M • COVID-19 activity driving increased molecular diagnostic sales • Expecting potential doubling of total sample-to-answer revenue in Q2 2020 vs. Q2 2019 (~$18M in Q2 2019) • Experiencing very strong demand for our NxTAG® Respiratory Patho
Slide 18: Summary of the Convertible Notes Offering
SUMMARY OF THE CONVERTIBLE NOTES OFFERING KEY TRANSACTION TERMS Offering size: $260M Maturity: May 15, 2025 (5 year) Coupon: 3% Conversion premium: 25% (up 100% with call spread) Call features: ~$220M after call spread & fees Investor puts: None Ranking: Senior unsecured Offering format: 4(a)(2) pri
Slide 19: Luminex Investment Highlights
LUMINEX INVESTMENT HIGHLIGHTS DIVERSIFIED PRODUCT SERVING MULTI-BILLION OFFERINGS DOLLAR MARKETS • Automated & Flexible Targeted & • Life Science Research Syndromic MDx Solutions • Clinical Diagnostics • Non-Automated MDx Solutions • Life Science and Clinical Tools EXCITING NEW PRODUCT PIPELINE RAZO
Slide 20: Thank You
Luminex. complexity simplified. THANK YOU